S. Korea To Triple Support For Embryonic Stem Cell Research
This article was originally published in PharmAsia News
Executive SummarySouth Korea plans to triple funding for embryonic stem cell research in an effort to boost the ability of local biotechnology companies to establish intellectual property rights. The increase, scheduled over the next five years, would raise the national budget for the research to nearly $100 million. The administration said it was concerned research in the country had declined too much in the wake of fraudulent action by an internationally known South Korean scientist. That case led to a three-year ban on the research, lifted in April. About 20 research laboratories are to share in the increased budget over the next two years. (Click here for more
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.